Frédéric Rolland
Impact in
- Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Head and Neck Cancer Studies 39
-
- Renal cell carcinoma treatment 51
- Prostate Cancer Treatment and Research 18
- Prostate Cancer Diagnosis and Treatment 5
- Co-authors
- Bernard J. Escudier (25 shared papers)Stéphane Marie. Oudard (33 shared papers)Sylvie Négrier (16 shared papers)Christine Chevreau (32 shared papers)Tomasz Demkow (4 shared papers)Thomas E. Hutson (4 shared papers)Cezary A. Szczylik (3 shared papers)Ronald M. Bukowski (3 shared papers)
- Journals
- Annals of Oncology (32 papers)European Journal of Cancer (27 papers)Journal of Clinical Oncology (11 papers)The Lancet Oncology (9 papers)European Urology (8 papers)
- Partner nations
- FranceUnited StatesBelgium
In The Last Decade
Frédéric Rolland
148 papers receiving 18.3k citations
Frédéric Rolland's Hit Papers
Peers
Comparison fields: 5 of 112
- Otorhinolaryngology 4.3k
- Pulmonary and Respiratory Medicine 8.1k
- Oncology 2.9k
- Surgery 1.4k
- Cancer Research 429
Countries citing papers authored by Frédéric Rolland
This map shows the geographic impact of Frédéric Rolland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Rolland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Rolland more than expected).
Fields of papers citing papers by Frédéric Rolland
This network shows the impact of papers produced by Frédéric Rolland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Rolland. The network helps show where Frédéric Rolland may publish in the future.
Co-authors
The 25 scholars most cited alongside Frédéric Rolland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 151 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 2 | Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Hit paper breakdown → | 2004 | 2517 |
| 3 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Hit paper breakdown → | 2018 | 1385 |
| 4 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1353 |
| 5 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 936 |
| 6 | Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy Hit paper breakdown → | 2007 | 845 |
| 7 | Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 682 |
| 8 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2013 | 575 |
| 9 | Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 404 |
| 10 | Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Hit paper breakdown → | 2015 | 378 |
| 11 | Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study Hit paper breakdown → | 2013 | 306 |
| 12 | Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 303 |
| 13 | 2009 | 223 | |
| 14 | 2008 | 213 | |
| 15 | 2011 | 199 | |
| 16 | 2015 | 184 | |
| 17 | 2006 | 162 | |
| 18 | Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2021 | 157 |
| 19 | 2007 | 153 | |
| 20 | 2014 | 144 |
About Frédéric Rolland
Frédéric Rolland is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Immunology, having authored 151 papers that have together received 18.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (51 papers), Head and Neck Cancer Studies (39 papers), Prostate Cancer Treatment and Research (18 papers), Cancer Immunotherapy and Biomarkers (14 papers), Bladder and Urothelial Cancer Treatments (14 papers), Testicular diseases and treatments (6 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Salivary Gland Tumors Diagnosis and Treatment (4 papers). The work is most often cited by research in Otorhinolaryngology (4.3k citations), Pulmonary and Respiratory Medicine (8.1k citations), Oncology (2.9k citations), Surgery (1.4k citations) and Cancer Research (429 citations). Frédéric Rolland has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include Bernard J. Escudier, Stéphane Marie. Oudard, Sylvie Négrier, Christine Chevreau, Tomasz Demkow, Thomas E. Hutson, Cezary A. Szczylik, Ronald M. Bukowski, Martin Eric Gore and Minghua Shan. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, The Lancet Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.